Cargando…

Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis

BACKGROUND: The role of chemoradiotherapy in unresectable locally advanced pancreatic cancer is still unclear. METHODS: Data from patients with unresectable locally advanced pancreatic cancer were extracted from the Surveillance, Epidemiology, and End Results Program database. Univariate and multiva...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zi-Meng, Ma, Hong-Bin, Meng, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077630/
https://www.ncbi.nlm.nih.gov/pubmed/37020202
http://dx.doi.org/10.1186/s12876-023-02739-x
_version_ 1785020346002309120
author Wang, Zi-Meng
Ma, Hong-Bin
Meng, Yan
author_facet Wang, Zi-Meng
Ma, Hong-Bin
Meng, Yan
author_sort Wang, Zi-Meng
collection PubMed
description BACKGROUND: The role of chemoradiotherapy in unresectable locally advanced pancreatic cancer is still unclear. METHODS: Data from patients with unresectable locally advanced pancreatic cancer were extracted from the Surveillance, Epidemiology, and End Results Program database. Univariate and multivariate Cox regression analyses were conducted to identify the independent prognostic factors of survival. Propensity score matching was carried out to minimize the interference of confounding factors. Subgroup analysis was performed to screen the characteristics of patients who would benefit from chemoradiotherapy. RESULTS: A total of 5002 patients with unresectable locally advanced pancreatic cancer were included. Among them, 2423 (48.4%) received chemotherapy, and 2579 (51.6%) received chemoradiotherapy. The median overall survival of all patients was 11 months. Multivariate Cox analysis showed that age (p < 0.001), marital status (p < 0.001), tumor size (p = 0.001), N stage (p = 0.015) and radiotherapy (p < 0.001) were independent prognostic factors of survival. Both before (HR, 0.817; 95% CI, 0.769–0.868; p < 0.001) and after (HR, 0.904; 95% CI, 0.876–0.933; p < 0.001) propensity score matching, chemoradiotherapy significantly improved the median overall survival of patients from 10 to 12 months. Subgroup analysis showed that chemoradiotherapy was significantly associated with improved survival regardless of sex, primary site or N stage. In addition, the following subgroups all significantly benefited from chemoradiotherapy: age ≥ 50 years, not divorced, grade 2–4, tumor size > 2 cm, adenocarcinoma, mucinous adenocarcinoma and white race. CONCLUSIONS: Chemoradiotherapy is highly recommended for patients with unresectable locally advanced pancreatic cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02739-x.
format Online
Article
Text
id pubmed-10077630
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100776302023-04-07 Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis Wang, Zi-Meng Ma, Hong-Bin Meng, Yan BMC Gastroenterol Research BACKGROUND: The role of chemoradiotherapy in unresectable locally advanced pancreatic cancer is still unclear. METHODS: Data from patients with unresectable locally advanced pancreatic cancer were extracted from the Surveillance, Epidemiology, and End Results Program database. Univariate and multivariate Cox regression analyses were conducted to identify the independent prognostic factors of survival. Propensity score matching was carried out to minimize the interference of confounding factors. Subgroup analysis was performed to screen the characteristics of patients who would benefit from chemoradiotherapy. RESULTS: A total of 5002 patients with unresectable locally advanced pancreatic cancer were included. Among them, 2423 (48.4%) received chemotherapy, and 2579 (51.6%) received chemoradiotherapy. The median overall survival of all patients was 11 months. Multivariate Cox analysis showed that age (p < 0.001), marital status (p < 0.001), tumor size (p = 0.001), N stage (p = 0.015) and radiotherapy (p < 0.001) were independent prognostic factors of survival. Both before (HR, 0.817; 95% CI, 0.769–0.868; p < 0.001) and after (HR, 0.904; 95% CI, 0.876–0.933; p < 0.001) propensity score matching, chemoradiotherapy significantly improved the median overall survival of patients from 10 to 12 months. Subgroup analysis showed that chemoradiotherapy was significantly associated with improved survival regardless of sex, primary site or N stage. In addition, the following subgroups all significantly benefited from chemoradiotherapy: age ≥ 50 years, not divorced, grade 2–4, tumor size > 2 cm, adenocarcinoma, mucinous adenocarcinoma and white race. CONCLUSIONS: Chemoradiotherapy is highly recommended for patients with unresectable locally advanced pancreatic cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02739-x. BioMed Central 2023-04-05 /pmc/articles/PMC10077630/ /pubmed/37020202 http://dx.doi.org/10.1186/s12876-023-02739-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Zi-Meng
Ma, Hong-Bin
Meng, Yan
Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis
title Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis
title_full Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis
title_fullStr Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis
title_full_unstemmed Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis
title_short Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis
title_sort impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077630/
https://www.ncbi.nlm.nih.gov/pubmed/37020202
http://dx.doi.org/10.1186/s12876-023-02739-x
work_keys_str_mv AT wangzimeng impactofchemoradiotherapyonthesurvivalofunresectablelocallyadvancedpancreaticcanceraretrospectivecohortanalysis
AT mahongbin impactofchemoradiotherapyonthesurvivalofunresectablelocallyadvancedpancreaticcanceraretrospectivecohortanalysis
AT mengyan impactofchemoradiotherapyonthesurvivalofunresectablelocallyadvancedpancreaticcanceraretrospectivecohortanalysis